Primary gonadal failure in children with intracranial brain tumors treated with high dose alkylating agents and radiation sparing therapy: an institutional case series.

IF 1.2 4区医学 Q4 HEMATOLOGY Pediatric Hematology and Oncology Pub Date : 2025-04-01 Epub Date: 2025-03-20 DOI:10.1080/08880018.2025.2480741

Sylvia Cheng, Sarah Riedlinger, Rebecca Ronsley, Laura Stewart, Juliette Hukin, Carol K L Lam

{"title":"Primary gonadal failure in children with intracranial brain tumors treated with high dose alkylating agents and radiation sparing therapy: an institutional case series.","authors":"Sylvia Cheng, Sarah Riedlinger, Rebecca Ronsley, Laura Stewart, Juliette Hukin, Carol K L Lam","doi":"10.1080/08880018.2025.2480741","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment of young children with brain tumors may require the use of high dose chemotherapy with alkylating agents to avoid craniospinal irradiation. The objective of this study is to describe the probability of primary gonadal failure (PGF) in children with a malignant intracranial tumor treated with high-dose alkylating agents in children diagnosed less than age 8 years who were treated with this radiation-sparing approach at our institution. Patient demographics, oncological and endocrine diagnoses, treatment modalities, and laboratory values were collected. Descriptive statistics, Kaplan Meier survival curves, regression analysis, and T-tests were used in data analysis. Eight of 18 (44%) developed PGF. The probability of developing PGF is 11% at 5 years, and 31% at 10 years. Cyclophosphamide equivalent dose (CED) was higher and duration of follow-up was longer in children with PGF. PGF is common in children who received CED without irradiation, but further studies are needed to correlate CED dose and time to onset of PGF.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"178-185"},"PeriodicalIF":1.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2480741","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Treatment of young children with brain tumors may require the use of high dose chemotherapy with alkylating agents to avoid craniospinal irradiation. The objective of this study is to describe the probability of primary gonadal failure (PGF) in children with a malignant intracranial tumor treated with high-dose alkylating agents in children diagnosed less than age 8 years who were treated with this radiation-sparing approach at our institution. Patient demographics, oncological and endocrine diagnoses, treatment modalities, and laboratory values were collected. Descriptive statistics, Kaplan Meier survival curves, regression analysis, and T-tests were used in data analysis. Eight of 18 (44%) developed PGF. The probability of developing PGF is 11% at 5 years, and 31% at 10 years. Cyclophosphamide equivalent dose (CED) was higher and duration of follow-up was longer in children with PGF. PGF is common in children who received CED without irradiation, but further studies are needed to correlate CED dose and time to onset of PGF.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用高剂量烷基化剂和放射保留疗法治疗颅内脑肿瘤儿童的原发性性腺功能衰竭：一个机构病例系列。

儿童脑肿瘤的治疗可能需要使用烷基化剂的大剂量化疗，以避免颅脑辐照。本研究的目的是描述在我们的机构中诊断为小于8岁的儿童在接受这种免辐射治疗的高剂量烷基化剂治疗的恶性颅内肿瘤的原发性性腺功能衰竭（PGF）的概率。收集患者人口统计学、肿瘤和内分泌诊断、治疗方式和实验室值。资料分析采用描述性统计、Kaplan Meier生存曲线、回归分析和t检验。18例中有8例（44%）发生PGF。5年发生PGF的概率为11%，10年为31%。PGF患儿环磷酰胺当量剂量（CED）较高，随访时间较长。PGF在接受了无辐照CED的儿童中很常见，但需要进一步研究CED剂量和时间与PGF发病的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pediatric Hematology and Oncology 医学-小儿科

CiteScore

2.60

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.